Literature DB >> 11745299

High-dose chemotherapy shows a dose-dependent toxicity to bone marrow osteoprogenitors: a mechanism for post-bone marrow transplantation osteopenia.

A Banfi1, M Podestà, L Fazzuoli, M R Sertoli, M Venturini, G Santini, R Cancedda, R Quarto.   

Abstract

BACKGROUND: Osteoporosis is a sequela of hemopoietic cell transplantation with a complex multifactorial pathogenesis in which the relative role of chemotherapy and irradiation is not completely understood. Therefore, the authors investigated the toxicity of chemotherapy-only conditioning regimens on bone homeostasis and bone marrow osteoprogenitors, its dose dependency, and the mechanism of chemotherapy-induced osteopenia.
METHODS: Fifty-one patients with high-grade non-Hodgkin lymphoma or breast carcinoma who had been treated previously with high-dose + peripheral blood progenitor cell or conventional chemotherapy or who had not received any treatment (prechemotherapy) were enrolled. The authors measured the bone marrow colony-forming unit fibroblast (CFU-f) and long-term culture-initiating cell frequency, forearm bone mineral density, serum osteotropic hormones and metabolic markers of bone formation (plasma osteocalcin), and resorption (urinary collagen I C-crosslinks).
RESULTS: Both high-dose chemotherapy regimens caused a 50% reduction in CFU-f frequency, independently of gonadal function status, whereas conventional chemotherapy and prechemotherapy groups were unaffected. Bone mineral density was measured in 26 non-Hodgkin lymphoma patients and again only high-dose chemotherapy caused a 10% loss in cortical bone and 20% in trabecular bone. No endocrine abnormality was found except for the secondary amenorrhea uniformly induced in the high-dose chemotherapy group. In these patients, plasma osteocalcin unexpectedly failed to increase in response to the menopausal increase in bone resorption rate, showing a selective impairment of the osteoblast compartment to cope with increased functional demand.
CONCLUSIONS: Chemotherapy without irradiation shows a dose-dependent toxicity to bone marrow stromal osteoprogenitors and can cause osteopenia by direct damage of the osteoblastic compartment, as a mechanism distinct from and summable to hypogonadism. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Year:  2001        PMID: 11745299     DOI: 10.1002/1097-0142(20011101)92:9<2419::aid-cncr1591>3.0.co;2-k

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  25 in total

1.  Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies.

Authors:  L Tauchmanovà; C Selleri; M Esposito; C Di Somma; F Orio; G Bifulco; S Palomba; G Lombardi; B Rotoli; A Colao
Journal:  Osteoporos Int       Date:  2003-09-30       Impact factor: 4.507

2.  NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: endocrine challenges-thyroid dysfunction, growth impairment, bone health, & reproductive risks.

Authors:  Christopher C Dvorak; Clarisa R Gracia; Jean E Sanders; Edward Y Cheng; K Scott Baker; Michael A Pulsipher; Anna Petryk
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-17       Impact factor: 5.742

3.  Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?

Authors:  K Kananen; L Volin; K Laitinen; T Ruutu; M J Välimäki
Journal:  Osteoporos Int       Date:  2005-12-31       Impact factor: 4.507

4.  Myeloid malignancies and the microenvironment.

Authors:  Claudia Korn; Simón Méndez-Ferrer
Journal:  Blood       Date:  2016-11-15       Impact factor: 22.113

5.  Adipose-derived stem cells transfected with pEGFP-OSX enhance bone formation during distraction osteogenesis.

Authors:  Qing-guo Lai; Shao-long Sun; Xiao-hong Zhou; Chen-ping Zhang; Kui-feng Yuan; Zhong-jun Yang; Sheng-lei Luo; Xiao-peng Tang; Jiang-bo Ci
Journal:  J Zhejiang Univ Sci B       Date:  2014-05       Impact factor: 3.066

Review 6.  Bone management in hematologic stem cell transplant recipients.

Authors:  D L Kendler; J J Body; M L Brandi; R Broady; J Cannata-Andia; M J Cannata-Ortiz; A El Maghraoui; G Guglielmi; P Hadji; D D Pierroz; T J de Villiers; R Rizzoli; P R Ebeling
Journal:  Osteoporos Int       Date:  2018-09-03       Impact factor: 4.507

Review 7.  Transplantation osteoporosis.

Authors:  Peter R Ebeling
Journal:  Curr Osteoporos Rep       Date:  2007-03       Impact factor: 5.096

8.  Deregulation of the CXCL12/CXCR4 axis in methotrexate chemotherapy-induced damage and recovery of the bone marrow microenvironment.

Authors:  Kristen R Georgiou; Michaela A Scherer; Tristan J King; Bruce K Foster; Cory J Xian
Journal:  Int J Exp Pathol       Date:  2012-01-05       Impact factor: 1.925

9.  Neuropeptide Y regulates the hematopoietic stem cell microenvironment and prevents nerve injury in the bone marrow.

Authors:  Min Hee Park; Hee Kyung Jin; Woo-Kie Min; Won Woo Lee; Jeong Eun Lee; Haruhiko Akiyama; Herbert Herzog; Grigori N Enikolopov; Edward H Schuchman; Jae-sung Bae
Journal:  EMBO J       Date:  2015-04-27       Impact factor: 11.598

Review 10.  Chemotherapy-associated osteonecrosis in cancer patients with solid tumours: a systematic review.

Authors:  Katharine Shim; Mary J MacKenzie; Eric Winquist
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.